The quest for an AIDS vaccine: Is the CD8+ T-cell approach feasible?

Nature Reviews Immunology

Volumn 2, Issue 4, 2002, Pages 283-291

  McMichael, Andrew ^a   Hanke, Tomâs ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TETRAMER; UNCLASSIFIED DRUG; VIRUS VACCINE;

CELL ASSAY; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; ETHICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; INFECTION CONTROL; LICENSING; MEMORY CELL; NONHUMAN; POLITICS; PRIMATE; PRIME BOOST; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VACCINE PRODUCTION; VIRUS CLASSIFICATION; VIRUS ESCAPE; VIRUS INFECTION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; CD8+ T LYMPHOCYTE; CYTOTOXICITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; HIV; HUMANS;

EID: 0036547156     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri779     Document Type: Review

References (126)

1. Emini, E. A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
2. Silvera, P. et al. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Res. Hum. Retroviruses 10, 1295-1304 (1994).
3. Connor, R. I. et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552-1576 (1998).
4. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 638-659 (1998).
5. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein Nature 393, 705-711 (1998).
6. Gauduin, M. C. et al. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Med. 3, 1389-1393 (1997).
7. Moore, J. P. & Burton, D. R. HIV-1 neutralizing antibodies: how full is the bottle? Nature Med. 5, 142-144 (1999).
8. Poignard, P., Saphire, E. O., Parren, P. W. & Burton, D. R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19, 253-274 (2001).
9. Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, R. K. & Desrosiers, R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
10. Altman, J. D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
11. + memory T cells. J. Exp. Med 186, 859-865 (1997).
12. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med. 5, 518-525 (1999).
13. + T cells in acute infectious mononucleosis Nature Med. 2, 906-911 (1996).
14. + T-cell selection, function, and death in the primary immune response in vivo. J. Clin. Invest. 106, 1251-1261 (2000).
15. Ogg, G. S. et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral RNA load. Science 279, 2103-2106 (1998).
16. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827-1835 (1999).
17. + T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192, 63-75 (2000).
18. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes Nature 410, 106-111 (2001).
19. Zinkernagel, R. M. The role of antigen in maintaining T cell memory. Dev. Biol Stand. 82, 189-191 (1994).
20. Lau, L. L., Jamieson, B. D., Somasundaram, T. & Ahmed, R. Cytotoxic T-cell memory without antigen. Nature 369, 648-652 (1994).
21. Tough, D. F., Sun, S., Zhang, X. & Sprent, J. Stimulation of memory T cells by cytokines. Vaccine 18, 1642-1648 (2000).
22. Oehen, S., Waldner, H., Kundig, T. M., Hengartner, H. & Zinkernagel, R. M. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J. Exp. Med. 176, 1273-1281 (1992).
23. Jamieson, B. D. & Ahmed, R. T cell memory. Long-term persistence of virus-specific cytotoxic T cells. J. Exp. Med. 169, 1993-2005 (1989).
24. Kalams, S. A. & Walker, B. D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188, 2199-2204 (1998).
25. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function J. Exp. Med 188, 2205-2213 (1998).
26. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549-556 (1994).
27. Ahlers, J. D., Belyakov, I. M., Thomas, E. K. & Berzofsky, J. A. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 108, 1677-1685 (2001).
28. + T-helper and a T-killer cell. Nature 393, 474-478 (1998).
29. Schoenberger S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
30. Whitmire, J. K. et al. CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses. J. Immunol. 163, 3194-3201 (1999).
31. Bennett, S. R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
32. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68, 8056-8063 (1994).
33. Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044 (1995).
34. + human CTL clones induced by candidate AIDS vaccines J. Immunol. 153, 2787-2799 (1994).
35. McMichael, A. T cell responses and viral escape. Cell 93, 673-676 (1998).
36. + T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
37. Walker, B. D. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328, 345-348 (1987).
38. Goulder, P. J. et al. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J. Exp. Med. 192, 1819-1832 (2000).
39. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
40. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type I infection. J. Virol. 68, 6103-6110 (1994).
41. Wilson, J. D. et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS 14, 225-233 (2000).
42. McMichael, A. J. et al. The dynamics of the cellular immune response to HIV infection: implications for vaccination. Phil. Trans R. Soc. Lond. B Biol. Sci. 355, 1007-1011 (2000).
43. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983-11991 (2001).
44. Matano, T et al. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72, 164-169 (1998).
45. + lymphocytes. Science 283, 857-860 (1999).
46. + T cell depletion in simian immunodeficiency virus-infected macaques J. Exp. Med. 189, 991-998 (1999).
47. + lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment J. Virol. 75, 10187-10199 (2001).
48. Koenig, S. et al. Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression Nature Med. 1, 330-336 (1995).
49. Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-459 (1991).
50. Goulder, P. J. et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS Nature Med. 3, 212-217 (1997).
51. Borrow, P. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
52. Evans, D. T. et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nature Med. 5, 1270-1276 (1999).
53. Le Gall, S. et al. Net interacts with the μ subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8, 483-495 (1998).
54. Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D. & Baltimore, D. HIV-1 Net protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397-401 (1998).
55. Rowland-Jones, S. L. et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest 102, 1758-1765 (1998).
56. Dorrell. L. et al. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS 14, 1117-1122 (2000).
57. + lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. 107, 1303-1310 (2001).
58. Rowland-Jones, S. L. et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 341, 860-861 (1993).
59. Bernard, N. F., Yannakis, C. M., Lee, J. S. & Tsoukas, C. M. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons J. infect. Dis. 179, 538-547 (1999).
60. Pinto, L. A. et al. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96, 867-876 (1995).
61. Bienzle, D. et al. Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners. J. Infect. Dis. 182, 123-132 (2000).
62. Lifson, J. D. et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J. Virol. 74, 2584-2593 (2000).
63. Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
64. Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
65. Rose, N. F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 639-649 (2001).
66. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 415, 331-335 (2002).
67. Barouch, D. H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
68. Hanke, T. et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999).
69. Smith, S. M. et al. Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression. AIDS Res. Hum. Retroviruses 15, 1691-1701 (1999).
70. Webster, R. G. & Askonas, B. A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J. Immunol. 10, 396-401 (1980).
71. McMichael, A. J., Gotch, F., Cullen, P. Askonas, B. & Webster, R. G. The human cytotoxic T cell response to influenza A vaccination. Clin Exp. Immunol. 43, 276-284 (1981).
72. Mongkolsapaya, J. et al. Antigen-specific expansion of cytotoxic T lymphocytes in acute measles virus infection, J. Virol. 73, 67-71 (1999).
73. Layton, G. T. et al. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles. J. Immunol. 151, 1097-1107 (1993).
74. + T cells against the simian immunodeficiency virus gag protein. Epitope specificity and relevance to protective immunity. J. Immunol. 147, 3560-3567 (1991).
75. Weber, J. et al Immunogenicity of the yeast recombinant pl 7/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine 13, 831-834 (1995).
76. Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H. & Pircher, H. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182, 261-266 (1995).
77. Chen, W., Anton, L. C., Bennink, J. R. & Yewdell, J. W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses Immunity 12, 83-93 (2000).
78. Yewdell, J. W. & Bennink, J. R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999).
79. Ulmer J. B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (1993).
80. Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998).
81. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4, 397-402 (1998).
82. Le, T. P. et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 18, 1893-1901 (2000).
83. Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476-480 (1998).
84. MacGregor, R. R. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis. 178, 92-100 (1998).
85. MacGregor, R. R., Boyer, J. D., Ciccarelli, R. B., Ginsberg, R. S. & Weiner, D. B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J. Infect. Dis. 181, 406 (2000).
86. Ugen, K. E. et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 16, 1818-1821 (1998).
87. Boyer, J. D. et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J. Infect. Dis. 181, 476-483 (2000).
88. Calarota, S. et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351, 1320-1325 (1998).
89. Calarota, S. A. et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. Immunol. 163, 2330-2338 (1999).
90. Yewdell, J. W., Bennink, J. R., Smith, G. L. & Moss, B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl Acad. Sci. USA 82, 1785-1789 (1985).
91. Bennink, J. R., Yewdell, J. W., Smith, G. L., Moller C. & Moss, B Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells, Nature 311, 576-579 (1984).
92. Clements-Mann, M. L. et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177, 1230-1246 (1998).
93. Egan, M. A. et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, hostrange-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J. Infect. Dis. 171, 1623-1627 (1995).
94. Graham, B. S. et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 166, 244-252 (1992).
95. Kantakamalakul, W. et al. Cytotoxic T lymphocyte responses to vaccinia virus antigens but not HIV-1 subtype Eenvelope protein seen in HIV-1 seronegative Thais. Asian Pac. J. Allergy Immunol. 19, 17-22 (2001).
96. Zagury, D. et al. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 332, 726-731 (1988).
97. Carruth, L. M. et al. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. AIDS Res. Hum. Retroviruses 15, 1021-1034 (1999).
98. Girard, M., Habel, A. & Chanel, C. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview. C. R. Acad. Sci III 322, 959-966 (1999).
99. Kent, S. J. et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180-10188 (1998).
100. + T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. 167, 7180-7191 (2001).
101. Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl.)]. Zentralbl. Bakteriol. [B] 167, 375-390 (1978).
102. Stickl, H. et al. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch. Med. Wochenschr. 99, 2386-2392 (1974).
103. Barouch, D. H. et al. Reduction of simian-human immunodeficiency virus 89. 6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J. Virol. 75, 5151-5158 (2001).
104. + T lymphocytes by attenuated simian immunodeficiency virus. J. Virol. 74, 8762-8766 (2000).
105. + nef-specific cytotoxic T celis in vaccinated macaques. Nature Med. 1, 1167-1173 (1995).
106. Fuller, D. H. et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol. Cell Biol. 75, 389-396 (1997).
107. Allen, T M. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164, 4968-4978 (2000).
108. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164, 1602-1611 (2000).
109. + responses. J. Clin. Invest. 107, 341-349 (2001).
110. Rosenberg, E. S., LaRosa, L., Flynn, T., Robbins, G. & Walker, B. D. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol. Lett. 66, 89-93 (1999).
111. Zhang, C., Cornette, J. L., Berzofsky, J. A. & DeLisi, C. The organization of human leucocyte antigen class I epitopes in HIV genome products: implications for HIV evolution and vaccine design. Vaccine 15, 1291-1302 (1997).
112. Burrows, S. R. et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J. Exp. Med. 182, 1703-1715 (1995).
113. Klenerman, P. et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369, 403-407 (1994).
114. Reid, S. W. et al. Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J. Exp. Med. 184, 2279-2286 (1996).
115. Klenerman, P. & Zinkernagel, R. M. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394, 482-485 (1998).
116. Mortara, L. et al. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J. Virol. 72, 1403-1410 (1998).
117. Price, D. A. et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl Acad. Sci. USA 94, 1890-1895 (1997).
118. Kelleher, A. D. et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted CTL responses. J. Exp. Med. 193, 375-386 (2001).
119. Korber B. et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
120. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection Nature 412, 334-338 (2001).
121. Hsu, S. C. et al. Protective cytotoxic T lymphocyte responses against paramyxoviruses induced by epitope-based DNA vaccines: involvement of IFN-γ. Int. Immunol. 10, 1441-1447 (1998).
122. + lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice. J. Virol. 67, 1044-1049 (1993).
123. Fu, T. M., Friedman, A., Ulmer, J. B., Liu, M. A. & Donnelly, J. J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71, 2715-2721 (1997).
124. Rodriguez, F., Zhang, J. & Whitton, J. L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71, 8497-8503 (1997).
125. Seth, A. et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74, 2502-2509 (2000).
126. Belyakov, I. M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Med. 7, 1320-1326 (2001).